This site is intended for US healthcare professionals.
Hear Central
Hear Central
HEAR CENTRAL: YOUR HUB FOR PEDMARK® RESOURCES
Select the materials you need to stay informed about hearing preservation from Fennec Pharmaceuticals. After you complete the form, you’ll receive direct links to those you selected.
By submitting this form, you are consenting to disclose any information provided, including your name, email address, address, telephone number, and any other information (collectivety “Personal Information’) to Fennec Pharmaceuticals and its representatives, agents, and contractors. You may also receive relevant information, including marketing information, from Fennec Pharmaceuticals by mail, email, telephone and/or SMS/text message in the future to provide information or to offer enrollment in educational programs and programs intended to benefit patients using or eligible to use Fennec Pharmaceuticals therapies. You will have the ability to opt out from receiving communications from Fennec Pharmaceuticals at any time. To learn more about how your personal information is used, please see our privacy policy and terms & conditions.
Stay Connected
Fill out the form below to enroll and receive updates from Fennec or contact a member of the Fennec team. All fields are required.
By submitting this form, I confirm that I am at least 18 years old and agree to receive updates and be contacted by Fennec Pharmaceuticals, Inc. by mail, fax, telephone, email, or text message (message and data rates may apply) about Fennec products, services, programs, or for marketing purposes, including market research. Fennec will not sell or transfer your personal data to any unrelated third party or for any other purpose without your express permission. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Fennec. To learn more about how your personal information is used, please see our privacy policy and terms of use.
I understand I may opt out of receiving information within future communications.
IMPORTANT SAFETY INFORMATION
- PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.
- Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.
- PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.
- Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
- Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73 m2.
- Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.
- The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.
Please see full Prescribing Information for PEDMARK.
INDICATIONS AND USAGE
PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non‑metastatic solid tumors.
Limitations of Use
The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.